MEDICINOVA, INC. (NASDAQ:MNOV) Files An 8-K Entry into a Material Definitive Agreement

0
MEDICINOVA, INC. (NASDAQ:MNOV) Files An 8-K Entry into a Material Definitive Agreement

MEDICINOVA, INC. (NASDAQ:MNOV) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01


MEDICINOVA INC Exhibit
EX-5.1 2 d768153dex51.htm EX-5.1 EX-5.1    Exhibit 5.1 August 23,…
To view the full exhibit click here

About MEDICINOVA, INC. (NASDAQ:MNOV)

MediciNova, Inc. is a biopharmaceutical company. The Company is focused on acquiring and developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological disorders and MN-001 (tipelukast) for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). Its pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers. Its MN-166 is an oral, anti-inflammatory and neuroprotective agent, which inhibits macrophage migration inhibitory factor (MIF) and certain phosphodiesterases (PDEs). Its MN-001 is an orally bioavailable small molecule compound. Its MN-221 is a highly selective B2-adrenergic receptor agonist being developed for the treatment of acute exacerbations of asthma.